Semaglutide is the active ingredient in Ozempic and Rybelsus, and it is used to manage type 2 diabetes and obesity
Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
its a powerful tool in the fight against oxidative stress, environmental toxins, and premature aging
Alpha Rejuvenation does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on this website
Unlike pharmaceutical sleep aids, it does not appear to produce significant next-day sedation or impaired cognitive performance